AUGUST 2025 NEWSLETTER





MYELOMA SUPPORT GROUP

SUPPORT GROUP MONTHLY NEWSLETTER | Connecting Communities!

Thank you, support group leaders, for continuing to meet regularly, whether virtual, in person, or hybrid. We hope the resources below are helpful to you in preparation for and discussion at your August meetings!

IMF Blogs

- July 31: June and July 2025: What's New in Myeloma? Read here
- July 24: ASCO, EHA, & IMWG: Three-Fold Impact for Myeloma Researchers & the Patient Community Read here
- July 17: Access to a Long-Term Myeloma Specialist is Integral to Your Care Read here
- July 3: Top Takeaways from the IMWG Conference Series: Making Sense of Treatment (Part 1 of 2)
 Read here
- July 3: Top Takeaways from the IMWG Conference Series: Making Sense of Treatment (Part 2 of 2)
 Read here

Myeloma News and Updates

- IMF Mourns the Loss of Accomplished Attorney & Longtime Board Member Benson Klein Read here
- EU Approves SARCLISA® for the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Read here
- Blenrep Approved in the EU for Relapsed/Refractory Multiple Myeloma Read here
- U.S. FDA Extends Review Period for Blenrep for Relapsed/Refractory Myeloma Read here
- Health Canada Approves Blenrep Combinations for Relapsed/Refractory Multiple Myeloma Read here
- European Commission Approves Darzalex Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma Read here
- IMF Brings the Patient Voice & Science to FDA-ODAC Meeting; Advocates for BLENREP® in Triplet Drug Combinations for the Treatment of Relapsed/Refractory Myeloma Read here
- IMF's Brian D. Novis Research Grants: Celebrating 30 Years of Paving the Way for Transformative Breakthroughs in Myeloma Research Read here
- European Hematology Association (EHA) and the European Myeloma Network (EMN) Include Pepaxti in New Clinical Practice Guidelines for Relapsed/Refractory Multiple Myeloma (RRMM) Read here
- FDA Grants Accelerated Approval to Lynozyfic™ for Relapsed/Refractory Multiple Myeloma Read here
- IMF Proudly Announces EMA-CHMP Positive Qualification Advice to i2TEAMM Novel Biomarker Procedure Application on the Use of MRDnegCR as an Intermediate Early Endpoint for Conditional Market Approval in Myeloma Clinical Trial Read here
- FDA Eliminates REMS Program for Certain Autologous CAR T-cell Therapies Read here
- FDA Removes Required REMS Program for Approval of Abecma and for Breyanzi Read here
- Recent NY Times article about the power of coMMunity! Can You Love a Stranger? Read here
- Myeloma News from the Journals: July 2025 Read here



Improving Lives Finding the Cure

AUGUST 2025 NEWSLETTER





MYELOMA SUPPORT GROUP

IMF Resources & New/Updated Publications

- IMF Resource Library Learn more | Myeloma Terms and Definitions Read here | Tip Cards Read here
- Patient Handbook for Multiple Myeloma Read here
- Understanding Dexamethasone Read here
- Multiple Myeloma Medications Read here | Guide to Myeloma Drug Names Read here
- Clinical Trial Fact Sheets Read here | ABBV-383 Read here | K36 Read here

Videos, Podcasts, Modules & Replays

- Newly Diagnosed Multiple Myeloma: What's Changing in 2025? | ASCO & EHA Watch Here
- Replay: Virtual Myeloma Community Workshop: What's Next? Managing Myeloma at Relapse Watch Here
- Replay: Multiple Myeloma Clinical Trials Explained & QA | Expert Advice & Real Patient Stories <u>Watch</u>
 Here
- Relapsed Multiple Myeloma in 2025: What Every Patient Needs to Know Watch Here
- SC daratumumab + VRd with DR maintenance in TE NDMM: sustained MRD negativity in PERSEUS trial Watch Here
- Subcutaneous vs IV isatuximab + pomalidomide/dexamethasone in R/R MM: IRAKLIA phase 3 study
 Watch Here
- Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone in NDMM: MRD Negativity Rates and Safety Watch Here
- Long-term Outcomes of Cilta-cel in Relapsed/Refractory Multiple Myeloma Watch Here
- Top 10 Myeloma Breakthroughs from ASCO & EHA: Frontline Therapy, Early & Late Relapse, and CAR T-cell Insights <u>Watch Here</u>
- Multiple Myeloma Q&A: Why Diagnosis Can Take 12+ Months, MGUS, Costs & FDA News Watch Here
- Palliative Care in Multiple Myeloma: What It Really Means for Patients and Families Watch Here
- Top Myeloma Research Presented at ASCO, EHA & IMWG Webinar: The Patient Perspective <u>Watch</u> Here
- The Many Faces of Cancer podcast featuring IMF Support Group Director Becky Bosley Watch Here

IMF Seminars, Webinars, Workshops and Events

- August 9: In-Person Regional Community Workshop Seattle, WA Register Now
- August 15: In-Person Patient and Family Seminar Los Angeles, CA Register Now
- September 13: Miracles for Myeloma, 5K Run/Walk Clark, New Jersey Register Now
- September 27: In-Person Regional Community Workshop Waltham, MA Register Now
- October 3: In-Person Patient and Family Seminar Chicago, IL Register Now
- November 15: In-Person Regional Community Workshop Raleigh, NC Register Now



Improving Lives Finding the Cure

AUGUST 2025 NEWSLETTER





MYELOMA SUPPORT GROUP

Other News

- Gearing up for Blood Cancer Awareness Month this September
 Help more people in your community recognize and understand myeloma—share your story using
 #KNOWMYELOMA and visit knowmyeloma.org to get started. Your voice can lead newly diagnosed
 patients straight to the support they need.
- Get Ready for September-Order Your #KNOWMYELOMA Merch Now
 September is almost here! Grab your limited-edition #KNOWMYELOMA gear this August, so it arrives in time for Blood Cancer Awareness Month. Shop Here
- Help amplify the IMF with a Google review
 Your voice can help myeloma patients find the support they need when they
 search online. A Google review can help patients and families discover the IMF when they need it
 most. Please leave a quick review Here

IMF Fundraising Opportunities near you! Learn more

Support Group Meeting Topics & Virtual Speaker Availability Inquire: sqteam@myeloma.org

Johnson&Johnson







